EUVIMEDEUVIMED entdecken
Crossref

Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma

Margaret E Duckett, Katie M Curran, Shay Bracha, Haley J Leeper

Journal of the American Animal Hospital Association · 2024

DOI: 10.5326/jaaha-ms-7372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Animal Hospital Association, 2024. Verfasst von Margaret E Duckett und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University (M.D., K.M.C., H.L.); and. Hauptthemen laut MEDLINE: Dog Diseases, Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dogs diagnosed with multicentric lymphoma often relapse following induction therapy within the first year of treatment. The primary aim of this study was to evaluate the tolerability of a novel drug combination using melphalan, vincristine, and cytarabine (MOC) for the treatment of relapsed lymphoma. On day 1, dogs were treated with vincristine (0.5–0.6 mg/m 2 IV) and cytarabine (300 mg/m 2 IV over 4–6 hr or subcutaneously over 2 days). On day 7, dogs were treated with melphalan (20 mg/m 2 per os ). This 2 wk protocol was repeated for at least three cycles or until treatment failure. Twenty-six dogs were treated with MOC and met the inclusion criteria. Twenty-three dogs had toxicity data, and all experienced adverse events with the majority graded as mild. The overall response rate was 38%, which included 19% of dogs who achieved a complete response. The median progression-free survival was 29 days (range 1–280 days). The overall clinical benefit was 65% for a median of 37 days (range 33–280 days). MOC is a safe treatment option for relapsed lymphoma in dogs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesLymphomaAnimalsDogsMelphalanCytarabineVincristineRetrospective StudiesNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy Protocols

Substanzen

MelphalanCytarabineVincristine

Autor:innen und Institutionen

  • From the Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University (M.D., K.M.C., H.L.); and.
  • The Ohio State University, Columbus, Ohio (S.B.).

Zitieren

APA

Duckett, M. E., Curran, K. M., Bracha, S., & Leeper, H. J. (2024). Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma. Journal of the American Animal Hospital Association. https://doi.org/10.5326/jaaha-ms-7372

Vancouver

Duckett ME, Curran KM, Bracha S, Leeper HJ. Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma. Journal of the American Animal Hospital Association. 2024. doi:10.5326/jaaha-ms-7372

BibTeX
@article{Duckett2024,
  author = {Duckett, Margaret E and Curran, Katie M and Bracha, Shay and Leeper, Haley J},
  title = {Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma},
  journal = {Journal of the American Animal Hospital Association},
  year = {2024},
  doi = {10.5326/jaaha-ms-7372}
}
Kostenlos starten →